Grape King Bio Ltd (TPE: 1707)

Market Cap	21.04B
Revenue (ttm)	10.86B
Net Income (ttm)	1.42B
Shares Out	148.14M
EPS (ttm)	9.53
PE Ratio	14.90
Forward PE	n/a
Dividend	6.90 (4.93%)
Ex-Dividend Date	Jun 20, 2024

Volume	65,084
Open	140.50
Previous Close	140.00
Day's Range	140.50 - 142.50
52-Week Range	132.00 - 163.50
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distribution; and Original Design Manufacturer/Original Equipment Manufacturer segments. The company offers Chinese herbal, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, weight control, liver care, brain health, eye care, feminine health, and sensual ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2023, Grape King Bio's revenue was 10.64 billion, an increase of 2.35% compared to the previous year's 10.39 billion. Earnings were 1.45 billion, a decrease of -0.30%.